CP 55,940

CP 55,940
Systematic (IUPAC) name
2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 83002-04-4
ATC code  ?
PubChem CID 3086156
ChEMBL CHEMBL559612 Y
Chemical data
Formula C24H40O3 
Mol. mass 376.573 g/mol

CP 55,940 is a cannabinoid which mimics the effects of naturally occurring THC (one of the psychoactive compounds found in marijuana). CP 55,940 was created by Pfizer in 1974 but was never marketed. It is currently used to study the endocannabinoid system. Some effects that have been noted are a greatly decreased rates of lever pressing in exposed mice, and a greater reaction to opiates in exposed mice. CP 55,940 is 45 times more potent than Δ9-THC, and fully antagonized by rimonabant (SR141716A).[1] CP 55,940 is considered a full agonist at both CB1 and CB2 receptors and has Ki values of 0.58nM and 0.68nM respectively, but is an antagonist at GPR55, the putative "CB3" receptor.[2]

There is no information on the dangers or neurotoxicity of CP 55,940 except what can be inferred from its similarity to other cannabinoids, which typically exhibit neuroprotective properties.

See also

References

  1. ^ Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière JC, Soubrié P, Le Fur G. et al. (1996). "Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain". Life Sci 1996 (58): 1239–47. PMID 8614277. 
  2. ^ Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME (October 2009). "Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands". The Journal of Biological Chemistry 284 (43): 29817–27. doi:10.1074/jbc.M109.050187. PMC 2785612. PMID 19723626. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2785612.